![](https://cdn.sanity.io/images/0vv8moc6/genetherapy/e6f0ab19e1a0a27fea9942e404a5dc4645e41830-300x300.jpg?fit=crop&auto=format)
Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention
Tr1X has dosed the first patient in a phase 1 clinical trial (NCT06462365) evaluating TRX103, an investigational allogeneic regulatory T-cell (allo-Treg) therapy, for the prevention of graft versus host disease (GvHD) in patients undergoing HLA-mismatched …